| Primary |
| Myelodysplastic Syndrome |
46.0% |
| Acute Myeloid Leukaemia |
20.4% |
| Myeloid Leukaemia |
9.3% |
| Drug Use For Unknown Indication |
8.1% |
| Product Used For Unknown Indication |
4.4% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Chronic Myelomonocytic Leukaemia |
1.8% |
| Prophylaxis |
1.2% |
| Refractory Anaemia |
1.0% |
| Chronic Myeloid Leukaemia |
0.8% |
| Colorectal Cancer Metastatic |
0.8% |
| Ovarian Cancer |
0.8% |
| Refractory Anaemia With An Excess Of Blasts |
0.6% |
| Acute Myeloid Leukaemia Recurrent |
0.4% |
| Acute Myelomonocytic Leukaemia |
0.4% |
| Antiemetic Supportive Care |
0.4% |
| Antiviral Prophylaxis |
0.4% |
| Hypertension |
0.4% |
| Ill-defined Disorder |
0.4% |
| Paroxysmal Nocturnal Haemoglobinuria |
0.4% |
|
| White Blood Cell Count Decreased |
14.8% |
| Death |
11.9% |
| Off Label Use |
7.4% |
| Pyrexia |
6.3% |
| Thrombocytopenia |
5.7% |
| Sepsis |
5.1% |
| Vomiting |
5.1% |
| Infection |
4.5% |
| Toxicity To Various Agents |
4.5% |
| Pancytopenia |
4.0% |
| Respiratory Failure |
4.0% |
| Peritonitis |
3.4% |
| Platelet Count Decreased |
3.4% |
| Rash |
3.4% |
| Somnolence |
3.4% |
| Bone Marrow Failure |
2.8% |
| Febrile Neutropenia |
2.8% |
| Thrombotic Thrombocytopenic Purpura |
2.8% |
| Decubitus Ulcer |
2.3% |
| Haemolytic Anaemia |
2.3% |
|
| Secondary |
| Myelodysplastic Syndrome |
57.9% |
| Acute Myeloid Leukaemia |
10.5% |
| Neoplasm Malignant |
10.5% |
| Paroxysmal Nocturnal Haemoglobinuria |
10.5% |
| Drug Use For Unknown Indication |
5.3% |
| Nausea |
5.3% |
|
| White Blood Cell Count Decreased |
20.0% |
| Blood Bilirubin Increased |
10.0% |
| Febrile Neutropenia |
10.0% |
| Prothrombin Time Shortened |
10.0% |
| Refractory Anaemia |
10.0% |
| Sepsis |
10.0% |
| Tachycardia |
10.0% |
| Tuberculosis |
10.0% |
| Venoocclusive Liver Disease |
10.0% |
|
| Concomitant |
| Myelodysplastic Syndrome |
24.3% |
| Product Used For Unknown Indication |
11.9% |
| Chemotherapy |
7.0% |
| Idiopathic Thrombocytopenic Purpura |
7.0% |
| Diabetes Mellitus |
6.5% |
| Drug Use For Unknown Indication |
5.9% |
| Iron Overload |
5.9% |
| Paroxysmal Nocturnal Haemoglobinuria |
4.3% |
| Acute Myeloid Leukaemia |
3.8% |
| Gastrooesophageal Reflux Disease |
3.2% |
| Anxiety |
2.2% |
| Blood Pressure |
2.2% |
| Deep Vein Thrombosis |
2.2% |
| Depression |
2.2% |
| Headache |
2.2% |
| Herpes Zoster |
2.2% |
| Iron Metabolism Disorder |
2.2% |
| Malabsorption |
2.2% |
| Neoplasm |
1.6% |
| Abdominal Pain Upper |
1.1% |
|
| Acute Myeloid Leukaemia |
11.9% |
| Weight Decreased |
11.9% |
| White Blood Cell Count Decreased |
10.2% |
| Pyrexia |
8.5% |
| Drug Ineffective |
5.1% |
| Medication Error |
5.1% |
| Rash |
5.1% |
| Disease Progression |
3.4% |
| Mouth Haemorrhage |
3.4% |
| Myelodysplastic Syndrome |
3.4% |
| Neurological Decompensation |
3.4% |
| Platelet Count Decreased |
3.4% |
| Renal Failure |
3.4% |
| Renal Failure Acute |
3.4% |
| Thrombocytopenia |
3.4% |
| Transfusion Reaction |
3.4% |
| Urinary Retention |
3.4% |
| Vomiting |
3.4% |
| White Blood Cell Count Increased |
3.4% |
| Abdominal Pain |
1.7% |
|
